rc118
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT04914117)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Claudin-18BINDING AGENT
CLDN18 binding agent
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06038396 | Phase 1/Phase 2 (Phase 2) | Aug 3, 2023 | Fudan University, RemeGen |
| NCT05205850 | Phase 1/Phase 2 (Phase 2) | Mar 3, 2022 | Fudan University, RemeGen |
| NCT04914117 | Phase 1 | Dec 31, 2021 | RemeGen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RemeGen | For profit | 3 | 3 | 2 | 2021 |
| Fudan University | Academic/Hospital | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1